<i>In vitro</i> activity of lactone ketolide nafithromycin (WCK 4873) against <i>Streptococcus pneumoniae</i> isolates enriched with macrolide-resistance phenotype collected from mainland China

Abstract

Nafithromycin exhibited therapeutically relevant <i>in vitro</i> antibacterial activity against contemporary highly resistant pneumococci collected from mainland China. This study supports the clinical development of nafithromycin for the management of CABP caused by pneumococci in China.